Status:
COMPLETED
New Nasal Applicator / New Formulation - User Study
Lead Sponsor:
AstraZeneca
Conditions:
Seasonal Allergic Rhinitis
Eligibility:
All Genders
6+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to compare the efficacy of once daily dosing with Rhinocort Aqua (new formulation) against Rhinocort Aqua (current formulation) and placebo in reliving the symptoms of sea...
Eligibility Criteria
Inclusion
- In the opinion of the investigator, is a candidate for treatment with nasal steroids based on a history of either a) inadequate control of symptoms with antihistamines, decongestants and/or immunotherapy, or b) prior successful treatment with nasal steroids.
- A documented history of at least one year of seasonal allergic rhinitis.
- A positive response to a skin prick test for grass allergens that must be present in the subject's environment throughout the study.
Exclusion
- Primary or secondary adrenal insufficiency
- Nasal candidiasis, rhinitis medicamentosa, acute or chronic sinusitis, influenza, upper respiratory tract infection or structural abnormalities of the nose (e.g., septal deviation, nasal polyps) symptomatic enough to cause significant nasal obstruction as judged by the investigator.
- A diagnosis of asthma requiring treatment as specified in the protocol.
Key Trial Info
Start Date :
April 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2002
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00641979
Start Date
April 1 2002
End Date
August 1 2002
Last Update
January 24 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.